The FDA also approved the therascreen KRAS RGQ PCR Kit (QIAGEN GmbH) as a companion diagnostic device for identifying eligible patients. Approval of sotorasib with panitumumab was based on ...

In a related action, the FDA approved the therascreen KRAS RGQ PCR Kit (QIAGEN GmbH) as a companion diagnostic device to help determine which patients with colorectal cancer have tumors that ...

The FDA also approved the therascreen KRAS RGQ PCR Kit (QIAGEN GmbH) as a companion diagnostic device to aid in identifying patients with colorectal cancer whose tumors harbor KRAS G12C mutations and ...

The global respiratory diagnostics market, valued at US$ 5.85 billion in 2023, is forecasted to grow at a robust CAGR of 6.5%, reaching US$ ...

DNA from frozen mESCs pellets was extracted using DNeasy Blood and Tissue Kit (Qiagen GmbH, Hilden, Germany). Purified genomic DNA was quantified with Qubit (Invitrogen, Carlsbad, CA, USA) according ...

In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Qiagen (QGEN – Research Report). The company’s ...

Kepler Capital analyst Maja Pataki maintained a Hold rating on Qiagen (QGEN – Research Report) on February 6 and set a price target of €42.17.

EPS; adj. operating income margin improves 1.8 percentage points to 28.7% QIAGEN expects the solid growth pace in H2 2024 to continue in 2025. Net sales are expected to rise about 4% CER (and core ...

QIAGEN announced earlier in January plans for the repurchase, which comes after QIAGEN returned approximately $300 million to shareholders in early 2024 also through a synthetic share repurchase.